Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

BACKGROUND: Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibod...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Immunol
Auteurs principaux: Borghi, Maria Orietta, Beltagy, Asmaa, Garrafa, Emirena, Curreli, Daniele, Cecchini, Germana, Bodio, Caterina, Grossi, Claudia, Blengino, Simonetta, Tincani, Angela, Franceschini, Franco, Andreoli, Laura, Lazzaroni, Maria Grazia, Piantoni, Silvia, Masneri, Stefania, Crisafulli, Francesca, Brugnoni, Duilio, Muiesan, Maria Lorenza, Salvetti, Massimo, Parati, Gianfranco, Torresani, Erminio, Mahler, Michael, Heilbron, Francesca, Pregnolato, Francesca, Pengo, Martino, Tedesco, Francesco, Pozzi, Nicola, Meroni, Pier Luigi
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2020
Sujets:
Immunology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7593765/
https://ncbi.nlm.nih.gov/pubmed/33178218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.584241
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires